Available treatment options for the management of Lambert-Eaton myasthenic syndrome
- PMID: 16805718
- DOI: 10.1517/14656566.7.10.1323
Available treatment options for the management of Lambert-Eaton myasthenic syndrome
Abstract
Lambert-Eaton myasthenic syndrome is a rare, but reasonably well-understood, antibody-mediated autoimmune disease that is caused by serum auto-antibodies and results in muscle weakness and autonomic dysfunction. One half of the patients have an idiopathic form, the other half a tumour-associated form of the disease. Three randomised trials and a large number of smaller clinical studies have resulted in a number of drugs becoming available for the treatment of Lambert-Eaton myasthenic syndrome. Several drugs are available for the symptomatic treatment of the disease, including guanidine, aminopyridines or acetylcholinesterase inhibitors. Other therapies aim to deplete the serum autoantibodies or to suppress the immune system. For this purpose, immunomodulating strategies, such as intravenous immunoglobulins or plasmapheresis, or several immunosuppressive agents are available. Chemotherapy has successfully ameliorated the course of disease in Lambert-Eaton myasthenic syndrome patients with an underlying tumour.
Similar articles
-
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.Ann N Y Acad Sci. 1998 May 13;841:823-6. doi: 10.1111/j.1749-6632.1998.tb11024.x. Ann N Y Acad Sci. 1998. PMID: 9668336 No abstract available.
-
Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.Ann N Y Acad Sci. 1998 May 13;841:827-31. doi: 10.1111/j.1749-6632.1998.tb11025.x. Ann N Y Acad Sci. 1998. PMID: 9668337 No abstract available.
-
Treatment for Lambert-Eaton myasthenic syndrome.Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD003279. doi: 10.1002/14651858.CD003279.pub3. Cochrane Database Syst Rev. 2011. PMID: 21328260 Free PMC article. Review.
-
Lambert-Eaton myasthenic syndrome.Rev Neurol (Paris). 2004 Feb;160(2):177-80. doi: 10.1016/s0035-3787(04)70888-7. Rev Neurol (Paris). 2004. PMID: 15034474 Review.
-
Treatment for Lambert-Eaton myasthenic syndrome.Cochrane Database Syst Rev. 2003;(2):CD003279. doi: 10.1002/14651858.CD003279. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003279. doi: 10.1002/14651858.CD003279.pub2 PMID: 12804456 Updated. Review.
Cited by
-
Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 9. Pharmacol Res Perspect. 2015. PMID: 25692017 Free PMC article.
-
Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30. Neuropsychiatr Dis Treat. 2011. PMID: 21822385 Free PMC article.
-
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.Mol Neurobiol. 2015 Aug;52(1):456-63. doi: 10.1007/s12035-014-8887-2. Epub 2014 Sep 9. Mol Neurobiol. 2015. PMID: 25195700 Free PMC article. Review.
-
Paraneoplastic syndromes in small cell lung cancer.J Thorac Dis. 2020 Oct;12(10):6253-6263. doi: 10.21037/jtd.2020.03.88. J Thorac Dis. 2020. PMID: 33209464 Free PMC article. Review.
-
Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.J Neurol. 2017 Sep;264(9):1854-1863. doi: 10.1007/s00415-017-8541-9. Epub 2017 Jun 12. J Neurol. 2017. PMID: 28608304 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
